Status of breast cancer in Latin American: Results of the breast cancer revealed initiative

Ayala, Natalia; Barchuk, Sabrina; Inurrigarro, Gloria; Celano, Constanza; Soriano, Jorge Luis; Bolaños, Patricia Escandón; Mohs-Alfaro, Mónica; Tapia, Héctor; Perez-Martinez, Ramón; Samtani, Suraj; Alvarado‐Cabrero, Isabel; Villarreal‐Garza, Cynthia; Tamez-Salazar, Jaime; Magallanes, Gerardo; Vázquez, Daniela; Castro, Janeth; Gómez‐Macías, Gabriela Sofía; Ferrigno, Ana S.; Morante, Zaida; Vilchez, Sheila; Cotrina, José M.; Doimi, Franco D.; Santander, Guianeya; Acevedo, Carlos; Ortega, Virginia; Lavista, Fernando; Richter, Lucía; Gianella, Mario; Paredes, María Teresa Victoria; Flores, Christian H.; Pinto, Joseph A.; Gómez, Henry

doi:10.1016/j.critrevonc.2022.103890

Cited by 5 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite this, our work delivers a first overview of the usage of ET in Chile, confirming the clinical impact of CDKis and leaving an open question regarding the potential survival benefit of first-line combined therapies in younger patients. Our study also reinforces the importance of RWD particularly within Latin America, where access disparities are extremely relevant and limit our interpretation of data coming from abroad [ 22 ] particularly when comparing sequence strategies if we consider patient attrition, with many women losing the window of opportunity for CDKi use. Finally, it provides local evidence to help define treatment guidelines, specifically in this case on whether CDKi should be available as first line treatment, given that today its reimbursement is restricted nationwide to patients progressing after a first line endocrine monotherapy.…”

Section: Discussionsupporting

confidence: 56%

Palbociclib in advanced stage hormone receptor-positive breast cancer: real- world data from a Chilean multicentre registry

Walbaum,

Reyes,

Rodriguez

et al. 2023

ecancer Journal

View full text Add to dashboard Cite

Background The addition of cyclin-dependent kinases inhibitors (CDKi) to endocrine therapy (ET) as the first- or second line treatment improves progression-free and overall survival (OS) in hormone receptor-positive, HER2 negative (HR+/HER2-) advanced stage breast cancer (ABC). Our study compared survival rates and prognostic factors in Chilean patients that used palbociclib as first or subsequent (≥second) lines of treatment in a real-world setting. Methods Our retrospective population-cohort study included HR+/HER2- ABC patients. We calculated 5-year OS and performed a multivariate analysis to determine prognostic factors. Results A total of 106 patients were included. Median age was 49 years (19–86), 28.3% (30) had de novo stage IV disease; 63% received palbociclib with ET as first line, 54% of them with aromatase inhibitor over fulvestrant. Median OS for the entire cohort was 99 months and 5-year OS was 69%. Patients that received first line palbociclib had a 5-year OS of 89% versus 43% for ET monotherapy or ≥second line palbociclib ( p = 0.0062). Multivariate analysis showed that the year at diagnosis and CDKi timing (first line versus ≥second line) were significantly associated with OS. Conclusion Our real-world data show that first-line CDKi + ET provides a statistically significant benefit in OS versus ≥second line in HR+/HER2- ABC patients.

show abstract

Section: Discussionsupporting

confidence: 56%

Palbociclib in advanced stage hormone receptor-positive breast cancer: real- world data from a Chilean multicentre registry

Walbaum,

Reyes,

Rodriguez

et al. 2023

ecancer Journal

View full text Add to dashboard Cite

show abstract

“…TNBC patients are less likely to be diagnosed in a screening mammography, leading to diagnosis being made at a more advance stage [ 11 , 14 ]. Moreover, In Latin America most cases are diagnosed in advanced stages due to the serious problem of limited access to breast cancer screenings in these countries [ 15 , 16 ] Asad et al found that the stage at diagnosis was the most significant factor for the rapid development of relapse of TNBC; with 55% of patients with stage III TNBC at diagnosis developing relapse, demonstrating a 15-fold higher probability of relapse compared to women with stage I [ 17 ]. The majority of our patients (78.1%) have a histologic grade III.…”

Section: Discussionmentioning

confidence: 99%

“…It has been reported, that the outcomes of Latin American breast cancer patients are worse compared to patients from developed countries. These poor outcomes are mainly associated with socioeconomic factors that not only limit access to screening, favoring late diagnosis, but also cause deficient access to specialised cancer care [ 15 , 16 ]. This should be one of the major priorities for intervention in our setting to achieve better short and long term outcomes in our population.…”

Section: Discussionmentioning

confidence: 99%

Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience

Piedra-Delgado,

Chambergo-Michilot,

Morante

et al. 2024

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background Evidence regarding differences in survival associated with the site of metastasis in triple-negative breast cancer (TNBC) remains limited. Our aim was to analyze the overall survival (OS), distant relapse free survival (DRFS), and survival since the diagnosis of the relapse (MS), according to the side of metastasis. Methods This was a retrospective study of TNBC patients with distant metastases at the Instituto Nacional de Enfermedades Neoplasicas (Lima, Peru) from 2000 to 2014. Prognostic factors were determined by multivariate Cox regression analysis. Results In total, 309 patients were included. Regarding the type of metastasis, visceral metastasis accounted for 41% and the lung was the most frequent first site of metastasis (33.3%). With a median follow-up of 10.2 years, the 5-year DRFS and OS were 10% and 26%, respectively. N staging (N2-N3 vs. N0, HR = 1.49, 95%CI: 1.04–2.14), metastasis in visceral sites (vs. bone; HR = 1.55, 95%CI: 0.94–2.56), the central nervous system (vs. bone; HR = 1.88, 95% CI: 1.10–3.22), and multiple sites (vs. bone; HR = 2.55, 95%CI:1.53–4.25) were prognostic factors of OS whereas multiple metastasis (HR = 2.30, 95% CI: 1.42–3.72) was a predictor of MS. In terms of DRFS, there were no differences according to metastasis type or solid organ. Conclusion TNBC patients with multiple metastasis and CNS metastasis have an increased risk of death compared to those with bone metastasis in terms of OS and MS.

show abstract

“…Cancers are among the most serious diseases that threaten human health [ 1 , 2 ]. Owing to the great complexity and heterogeneity of tumor microenvironment (TME), traditional monotherapy strategies (i.e., chemotherapy, surgery, radiotherapy) face challenges like low specificity, high recurrence rate, and unavoidable damage to normal tissues [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Metallic Copper-Based Dual-Enzyme Biomimetic Nanoplatform for Mild Photothermal Enhancement of Anticancer Catalytic Activity

Chen,

Li,

Xiang

et al. 2024

Biomater Res

View full text Add to dashboard Cite

Background: Chemodynamic therapy (CDT) is recognized as a promising cancer treatment. Recently, copper sulfide nanostructures have been extensively employed as Fenton-like reagents that catalyze the formation of acutely toxic hydroxyl radicals (·OH) from hydrogen peroxide (H 2 O 2 ). However, CDT therapeutic potency is restricted by the tumor microenvironment (TME), such as insufficient amounts of hydrogen peroxide, excessive glutathione levels, etc. To address these disadvantages, glucose oxidase (GOx) or catalase (CAT) can be utilized to enhance CDT, while low therapeutic efficacy still inhibits their future applications. Our previous study revealed that mild photothermal effect could boost the CDT catalytic effectiveness as well as GOx enzyme activity over a range. Results: We engineered and constructed a hollow CuS nanoplatform loaded with GOx and CAT, coating with macrophage membranes (M@GOx-CAT@CuS NPs). The nanoplatforms allowed enhancement of the reactive oxygen species creation rate and GOx catalytic activeness of CDT through mild phototherapy directed by photoacoustic imaging. After actively targeting vascular cell adhesion molecule-1 (VCAM-1) in cancer cells mediated by macrophage membrane coating, M@GOx-CAT@CuS NPs released GOx and CAT under near-infrared irradiation. GOx catalyzed the formation of H 2 O 2 and gluconic acid with glucose, creating a better catalytic environment for CDT. Meanwhile, CAT-catalyzed H 2 O 2 decomposition to generate sufficient oxygen, appropriately alleviating the oxygen shortage in the TME. In addition, starvation effects decreased adenosine triphosphate levels and further underregulated heat shock protein expression to reduce the heat resistance of tumor cells, resulting in a better mild phototherapy outcome. Both in vitro and in vivo experiments demonstrated that the newly developed M@GOx-CAT@CuS nanoplatform has remarkable synergistic anticancer therapeutic effects. Conclusion: The cascade reaction-enhanced biomimetic nanoplatform opens up a new avenue for precision tumor diagnostic and therapeutic research.

show abstract

Status of breast cancer in Latin American: Results of the breast cancer revealed initiative

Cited by 5 publications

References 13 publications

Palbociclib in advanced stage hormone receptor-positive breast cancer: real- world data from a Chilean multicentre registry

Palbociclib in advanced stage hormone receptor-positive breast cancer: real- world data from a Chilean multicentre registry

Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience

Metallic Copper-Based Dual-Enzyme Biomimetic Nanoplatform for Mild Photothermal Enhancement of Anticancer Catalytic Activity

Contact Info

Product

Resources

About